In the phase 1b CAMMA 1 trial, cevostamab plus pomalidomide and dexamethasone produced overall response rates of 86.2% to 88.0%.
|Poll|May 1, 2015
Neutropenia and Abdominal Pain in a 30-Year-Old Patient
Author(s)Brian Morse, MD
A 30-year-old man who recently underwent induction chemotherapy for bone marrow transplant is admitted with neutropenia and right lower-quadrant abdominal pain. What is your diagnosis?
Advertisement
A 30-year-old man who recently underwent induction chemotherapy for bone marrow transplant is admitted with neutropenia and right lower-quadrant abdominal pain. Coronal and axial images from a contrast-enhanced CT scan of the abdomen and pelvis are seen below (white dots and partial circle on images are artifacts).
What is your diagnosis?
Advertisement
Related to this article
Data from the phase 3 LITESPARK-011 trial support the FDA approval of belzutifan plus lenvatinib for adults with advanced clear cell renal cell carcinoma.
In the phase 1b portion of the MELT-MM trial, elranatamab plus mezigdomide produced a 100% overall response rate in relapsed/refractory multiple myeloma.
Xiuning Le, MD, PhD, discusses the confirmatory SOHO-02 trial needed to convert sevabertinib’s accelerated approval to full approval.
A pooled analysis of the AMY2009 and AMY3001 trials showed daratumumab plus VCd yielded hematologic complete responses in cardiac-involved AL amyloidosis.
Health Canada approved epcoritamab plus lenalidomide and rituximab for relapsed/refractory grade 1 to 3a follicular lymphoma, backed by the EPCORE FL-1 trial.
David R. Gandara, MD, discusses how EMPOWER-Lung 1’s findings in KRAS G12C-mutated disease should inform the design of combination trials.
Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA MCGP Panel Votes in Favor of the Galleri Multicancer Early Detection Test
2
Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC
3
FDA Grants Approval to Lirafugratinib for Advanced Cholangiocarcinoma with FGFR2 Alteration
4
Approaching Cardiovascular Risk in Prostate Cancer Hormonal Therapy
5